EUCTR2006-003696-12-CZ进行中（未招募）不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/A
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,011
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information [PHI]).
- •2.Aged 18 to 55 years old, inclusive, at the time of informed consent.
- •3.Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4 (Polman et al, 2005).
- •4.Must have a baseline EDSS between 0.0 and 5.0, inclusive.
- •5.Must have experienced at least 1 relapse within the 12 months prior to randomization, with a prior brain MRI demonstrating lesion(s) consistent with MS, or show evidence of Gd-enhancing lesion(s) of the brain on an MRI performed within the 6 weeks prior to randomization.
- •6.Male subjects and female subjects of child bearing potential (including female subjects who are not post-menopausal for at least 1 year) must be willing to practice effective contraception (as defined by the Investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical History
- •1.Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses, but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.
- •2.Unable to perform the Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) with both upper extremities, and PASAT 3.
- •3.Unable to perform visual function tests.
- •4.History of malignancy, unless an exception is granted by the Biogen Idec Medical Director. (Subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible.)
- •5.History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
- •6.History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or other major disease that would preclude participation in a clinical trial.
- •7.History of clinically significant cardiovascular, pulmonary, gastrointestinal, dermatologic, psychiatric, neurologic (other than MS), and/or other major disease that would preclude participation in a clinical trial.
- •8.History of human immunodeficiency virus (HIV).
- •9.History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.
- •10.An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.
- •11.Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.
- •12.Any of the following abnormal blood tests at screening:
- •alanine transaminase/serum glutamate-pyruvate transaminase (ALT/SGPT), or aspartate transaminase/serum glutamic-oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase (GGT) =2 times the upper limit of normal (ULN)
- •leukocytes <3500/mm³
- •eosinophils >0.7 x 10³/µL or >0.7 GI/L.
- •13.Any of the following abnormal urine tests at screening confirmed by a second urinalysis 2 weeks later:
- •proteinuria (1+ or greater)
- •hematuria, without known etiology (e.g., urinary tract infection, menses)
- •glycosuria, without known etiology (e.g., recent steroid use, elevated serum glucose).
- •Treatment History
- •14.Any previous treatment with FUMADERM® or BG00012 (FAG-201).
- •15.Prior treatment with any of the following:
- •total lymphoid irradiation
- •cladribine
- •T-cell or T-cell receptor vaccination
- •any therapeutic monoclonal antibody, with the exception of TYSABRI® (natalizumab) (see exclusion #17).
- •16.Prior treatment with any of the following within 1 year prior to randomization:
- •mitoxantrone
- •cyclophosphamide.
- •17.Prior treatment with any of the following medications or procedures within the 6 months prior to randomization:
- •cyclosporine
- •azathioprine
- •methotrexate
- •natalizumab (TYSABRI®)
- •intravenous immunoglobulin
- •plasmapheresis or cytapheresis.
- •18.Prior treatment with any of the following within the 3 months prior to randomization:
- •subcutaneous or oral glatiramer acetate
- •interferon-alpha
- •interferon-beta.
- •19.Treatment with any of the following medications within the 50 days prior to randomization:
- •steroids (intravenous [IV] or oral corticosteroid treatment, including agents that may act through the corticosteri
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/ARelapsing-Remitting Multiple SclerosisMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-003696-12-ATBiogen Idec Ltd.1,011
进行中（未招募）
1 期
A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.Pulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2019-002817-21-PTActelion Pharmaceuticals Ltd.237
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with cancer of the stomach spreading to other parts of the body - cancer does not respond to or continues to grow after standard chemotherapy (a combination of medicines including platinum or fluoropyrimidine drugs). Patients assigned to 1 of 2 groups: one group will receive IMC-1121B, the other group an inactive substance (placebo). Neither patient nor doctor will know the treatment group. All patients will be treated with paclitaxel.Metastatic gastric or gastroesophageal adenocarcinomaMedDRA version: 15.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020426-18-BEImClone LLC663
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and FluoropyrimidineMetastatic gastric or gastroesophageal adenocarcinomaMedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020426-18-BGImClone LLC663
进行中（未招募）
不适用
Study investigating new drug, IMC-1121B, in patients with cancer of the stomach spreading to other parts of the body - cancer does not respond to or continues to grow after standard chemotherapy (a combination of medicines including platinum or fluoropyrimidine drugs). Patients assigned to 1 of 2 groups: one group will receive IMC-1121B, the other group an inactive substance (placebo). Neither patient nor doctor will know the treatment group. All patients will be treated with paclitaxel.Metastatic gastric or gastroesophageal adenocarcinomaMedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020426-18-DEImClone LLC663